Reuters logo
BRIEF-Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU
August 24, 2017 / 11:21 PM / 3 months ago

BRIEF-Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU

Aug 24 (Reuters) - Biogen Inc

* Imraldi(®), Biogen’s Adalimumab Biosimilar referencing Humira(®), is approved in European Union

* European commission granted a marketing authorization for Imraldi, an Adalimumab Biosimilar referencing H

* umira Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below